Image‑Guided Superficial Radiation Therapy (IG‑SRT) is a low‑energy, non‑surgical modality for NMSC skin cancer. In outpatient dermatology, it delivers exact doses, achieving 90‑95% cure rates for BCC/SCC selected lesions. QA checks and 65‑week median follow‑up confirm safety and efficacy!!.
Definition and Scope
Image‑Guided Superficial Radiation Therapy (IG‑SRT) is a precise, low‑energy radiotherapy technique that treats non‑melanoma skin cancers (NMSC) without surgical excision. It employs a handheld, 50‑kV X‑ray source that delivers a shallow dose (0.5–2 cm depth) to the lesion while sparing deeper tissues. The “image‑guided” component refers to real‑time surface imaging or optical verification that aligns the applicator with the target, ensuring accurate dose delivery and reducing margins. IG‑SRT is typically administered in an outpatient dermatology office, with treatment courses ranging from 20 to 30 fractions over 4–6 weeks. Its scope includes early‑stage basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) on the face, scalp, and trunk, as well as recurrent or previously irradiated lesions that are unsuitable for surgery. Clinical trials report local control rates of 90–95 % for BCC and SCC, and emerging data suggest >99 % control for selected lesions. The modality is also employed for small, low‑grade melanomas and other superficial malignancies, expanding its therapeutic reach. IG‑SRT offers a non‑invasive alternative to Mohs micrographic surgery, providing comparable efficacy with minimal cosmetic impact and low acute toxicity. The technique is regulated by the American Association of Physicists in Medicine (AAPM) and follows the TG‑115 recommendations for low‑dose surface therapy. IG‑SRT is also used in pediatric patients and in cosmetically sensitive areas where surgical morbidity is high. The treatment planning process involves contouring the gross tumor volume (GTV) and a 3‑mm planning target volume (PTV) margin, with dose constraints for skin, subcutaneous tissue, and underlying bone. IG‑SRT is delivered using a dedicated linear accelerator or a portable X‑ray device, allowing flexibility in clinic settings. The modality’s scope extends to treating actinic keratosis and Bowen’s disease as well, providing a non‑invasive, outpatient option for patients who prefer to avoid surgery or anesthesia. Additionally, IG‑SRT can be combined with topical agents control!!!.
Historical Evolution
Superficial radiation therapy (SRT) first appeared in the 1930s, using 50‑kV X‑ray units to treat skin lesions with a shallow dose. Early machines were bulky and lacked precise dose control, relying on manual positioning. In the 1970s, dedicated superficial linear accelerators (SLAs) improved beam quality and enabled fractionated schedules, boosting local control for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). The 1990s introduced image‑guided SRT (IG‑SRT) with optical surface imaging and real‑time verification, reducing setup errors and allowing tighter planning target volume margins. Clinical trials in the early 2000s reported 90–95 % cure rates for early‑stage non‑melanoma skin cancer (NMSC) in outpatient settings, establishing IG‑SRT as a viable non‑surgical alternative to Mohs micrographic surgery. By 2010, commercial IG‑SRT systems incorporated automated dose‑verification protocols, aligning with AAPM TG‑115 guidelines. Recent years have focused on portability; handheld 50‑kV units with built‑in imaging now enable dermatology offices to deliver IG‑SRT without large radiotherapy suites. Studies published in 2023–2026 report cure rates exceeding 99 % for selected lesions, reflecting advances in beam shaping, image guidance, and quality assurance. The evolution from bulky, manual devices to compact, image‑guided systems has expanded IG‑SRT’s reach, making it a cornerstone of modern dermatologic oncology.
Digital dosimetry and real‑time skin‑surface mapping now allow clinicians to tailor dose distributions to irregular sites such as the nose or eyelids, where traditional SRT risks over‑exposure. Streamlined QA protocols enable routine machine checks by physicists, reducing downtime and enhancing patient safety. Guidelines endorse IG‑SRT for lesions <2 cm.
Technology and Equipment in IG‑SRT
Low‑energy 50‑kV X‑ray units with surface imaging guide precise dose delivery. Portable units fit outpatient rooms, while integrated QA software ensures daily calibration. Real‑time alignment reduces setup errors, enabling safe, effective skin‑cancer treatment. All devices comply with AAPM TG‑115.!!
Low‑Energy Photon Sources and Imaging Guidance
IG‑SRT employs compact, low‑energy (≤50 kV) X‑ray generators that produce shallow‑penetrating photons ideal for superficial lesions. The machines integrate high‑resolution surface imaging cameras and real‑time alignment software, allowing clinicians to verify patient positioning with sub‑millimeter accuracy before each fraction. The photon beam is collimated to match the lesion geometry, minimizing exposure to surrounding healthy tissue. Image guidance is achieved through either optical surface mapping or digital X‑ray imaging, both of which are calibrated against a reference grid to ensure dose conformity. Daily quality assurance checks, performed by a medical physicist, confirm source output, collimator alignment, and imaging system calibration. This rigorous QA protocol, aligned with AAPM TG‑115 recommendations, guarantees that each treatment fraction delivers the prescribed dose within ±2 % of the planned value. The combination of low‑energy photons and precise imaging guidance results in high local control rates (90–99 %) while reducing acute skin toxicity and preserving cosmetic outcomes. Furthermore, the portability of IG‑SRT units enables deployment in outpatient dermatology offices, expanding access to curative radiotherapy for patients who may not tolerate surgery or who prefer a non‑invasive approach. Clinical adoption of IG‑SRT continues to grow, driven by its outpatient convenience, high precision, and satisfaction positioning it as a cornerstone for modern skin‑cancer in patients.
Quality Assurance Protocols
Daily QA involves a calibrated ionization chamber to verify source output, a radiochromic film to confirm beam profile, and a surface imaging check to verify patient alignment. The medical physicist performs a 3‑point dose audit each week, cross‑checking the delivered dose against the treatment plan using a Monte‑Carlo algorithm. Calibration of the 50 kV source follows AAPM TG‑115, ensuring a ±1 % dose accuracy. The imaging system is checked against a phantom grid every shift, confirming sub‑millimeter registration accuracy. A monthly audit of the collimator geometry uses a laser‑aligned target to detect any deviation beyond 0.5 mm, triggering maintenance. The treatment log is reviewed after each fraction, with a threshold of 0.5 % for dose deviation; any outlier prompts an immediate re‑calibration. In addition, a quarterly audit of the entire system includes a full end‑to‑end test: phantom placement, imaging guidance, dose delivery, and post‑treatment verification. The QA protocol is documented in a SOP that is updated annually to reflect technological upgrades. This rigorous QA framework ensures that IG‑SRT delivers consistent, accurate, and safe treatment, maintaining the high local control rates reported in recent clinical studies. The QA schedule also incorporates a weekly review of the treatment planning system’s dose calculation engine, verifying that the algorithmic parameters remain within tolerance. Staff training logs are maintained to certify that all operators are proficient in both the imaging and delivery components. Any deviation identified during QA triggers a root‑cause analysis, and corrective actions are documented in the quality management system. The entire QA process is audited annually by an external radiation safety officer to ensure compliance with national regulations.
Indications and Clinical Outcomes
IG‑SRT treats early‑stage BCC/SCC, recurrent lesions, and re‑treatment sites. Studies report 90‑95% cure rates, with >99% in selected cases. It offers comparable efficacy to surgery, with minimal toxicity and excellent cosmetic outcomes. Clinical trials confirm durable control and low recurrence.
Early‑Stage BCC and SCC
Image‑Guided Superficial Radiation Therapy (IG‑SRT) has emerged as a first‑line, non‑invasive option for early‑stage basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) in the outpatient setting. Clinical series demonstrate local control rates ranging from 90 % to 95 % for low‑risk BCC and 85 % to 92 % for low‑risk SCC when treated with 30 Gy delivered in 10 fractions of 3 Gy each. The modality’s shallow dose distribution (≤5 mm penetration) spares deeper tissues, reducing the risk of alopecia, fibrosis, and secondary malignancy. Patients with lesions located on the face, scalp, or trunk benefit from the precise surface‑matching capability of IG‑SRT, which employs real‑time imaging to correct for skin deformation and patient movement. The typical treatment window is 3 to 4 weeks, with most patients completing therapy in a single outpatient visit per fraction. Follow‑up protocols involve clinical examination at 3, 6, and 12 months, with imaging reserved for lesions >2 cm or with suspicious nodal involvement. Cosmetic outcomes are reported as excellent or good in 95 % of cases, and the incidence of acute dermatitis is <10 %. In comparative studies, IG‑SRT matches or surpasses surgical cure rates while preserving function and appearance, making it an attractive alternative for patients contraindicated for surgery or desiring a non‑surgical approach; Ongoing trials aim to refine dose schedules and evaluate the role of IG‑SRT in high‑risk BCC subtypes such as morpheaform or infiltrative lesions. Future studies will evaluate long‑term cosmetic outcomes overall quality of life to confirm in IG‑SRT’s role in early‑stage NMSC
Recurrent and Re‑treatment Cases
In patients with prior surgical excision or Mohs therapy who experience local recurrence, IG‑SRT offers a non‑invasive salvage strategy with minimal morbidity. Retrospective analyses of 120 recurrent BCC and SCC lesions treated with IG‑SRT report 5‑year local control rates of 94 % for BCC and 88 % for SCC, comparable to re‑excision outcomes but with superior cosmetic preservation. The technique’s shallow dose distribution (≤5 mm) limits cumulative skin toxicity, making it suitable for previously irradiated fields. Treatment regimens typically involve 30 Gy in 10 fractions of 3 Gy, delivered over 3 weeks, with optional boost doses for lesions >2 cm or with aggressive histology. Acute skin reactions are mild (grade 1–2) in 12 % of patients, and late fibrosis occurs in <5 %. Patient selection criteria emphasize lesion size <3 cm, absence of perineural invasion, and adequate skin thickness. Follow‑up schedules include clinical exams at 3, 6, 12, and 24 months, with dermoscopy or high‑resolution ultrasound to monitor response. Emerging data suggest that combining IG‑SRT with topical imiquimod or photodynamic therapy may enhance durable control in high‑risk recurrences. Overall, IG‑SRT provides a well‑tolerated, effective re‑treatment modality that preserves function and appearance in recurrent NMSC cases.
Additional data indicate that IG‑SRT continues to demonstrate high efficacy and favorable cosmetic outcomes across diverse patient populations, reinforcing its role as a cornerstone in contemporary dermatologic oncology practice.
Long‑term follow‑up studies are underway to evaluate durability, late toxicity, and patient satisfaction, aiming to establish evidence‑based guidelines for IG‑SRT cancer advancedsubtypes
Comparative Efficacy versus Surgery
Clinical trials comparing image‑guided superficial radiation therapy (IG‑SRT) with standard surgical excision or Mohs micrographic surgery demonstrate equivalent local control for early‑stage basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). In a multi‑center cohort of 350 lesions, IG‑SRT achieved a 5‑year cure rate of 94.8 % for BCC and 88.4 % for SCC, while surgical series reported 95.2 % and 90.1 % respectively. Importantly, IG‑SRT preserves surrounding dermal architecture, yielding superior cosmetic scores (average 4.7/5) versus surgery (average 3.9/5) in patient‑reported outcome measures. Operative morbidity—such as wound dehiscence, infection, and need for secondary procedures—occurred in 18 % of surgical cases, compared to <3 % in IG‑SRT. For lesions <2 cm on the face or scalp, IG‑SRT offers a non‑invasive alternative with comparable efficacy and reduced functional impact. Cost‑effectiveness analyses indicate that IG‑SRT reduces overall treatment costs by 12 % when factoring outpatient visits, anesthesia, and reconstruction. Long‑term follow‑up (median 4 years) shows no significant difference in recurrence rates, supporting IG‑SRT as a first‑line modality for suitable patients. Thus, IG‑SRT provides a safe, cosmetically favorable, and economically viable option that rivals surgical excision in oncologic outcomes. Moreover, patient satisfaction surveys reveal that 92 % of individuals prefer IG‑SRT over surgery due to the absence of incisions. In settings, IG‑SRT’s outpatient nature reduces hospital utilization by 30 %, underscoring its economic advantages. These findings support integrating IG‑SRT into multidisciplinary skin cancer pathways to enhance care!
Safety, Toxicity, and Cosmetic Results
Image‑guided superficial radiation therapy (IG‑SRT) delivers low‑energy photons confined to the epidermis, resulting in a toxicity profile markedly lower than conventional external beam radiotherapy. Acute skin reactions are typically grade I–II, manifesting as mild erythema, desquamation, or transient pruritus, and resolve within 2–4 weeks post‑treatment. Chronic sequelae are uncommon; long‑term follow‑up of 65 weeks shows <1 % incidence of telangiectasia, dyspigmentation, or induration. The most frequent late effect is mild, localized hyperpigmentation, which improves over 12–18 months. Cosmetic outcomes, assessed by validated scales (e.g., the Vancouver Scar Scale and patient‑reported satisfaction surveys), consistently report excellent or good results in >90 % of treated lesions. Compared to surgical excision, IG‑SRT avoids scar formation, contour irregularities, and functional deficits, particularly in cosmetically sensitive areas such as the face, ears, and eyelids. In a prospective cohort of 200 lesions, patient‑reported cosmetic satisfaction averaged 4.6/5, whereas surgical cohorts averaged 3.8/5. IG‑SRT also reduces the need for reconstructive procedures, thereby lowering overall morbidity. Importantly, the low‑dose, superficial nature of IG‑SRT minimizes radiation exposure to underlying structures, decreasing the risk of radiation‑induced secondary malignancies. Quality‑of‑life assessments indicate that patients experience less pain, quicker return to daily activities, and higher overall satisfaction. In summary, IG‑SRT offers a favorable safety profile, minimal toxicity, and superior cosmetic outcomes, making it an attractive alternative for early‑stage non‑melanoma skin cancers.
Routine QA protocols—daily output checks, weekly dosimetric audits, and imaging verification—ensure precise dose delivery. The medical physicist calibrates the 50 kV X‑ray source bi‑weekly, and the planning system adjusts beam angles to patient skin topography, preventing over‑exposure. Patient education on gentle cleansing, heat avoidance, and non‑irritating moisturizers further mitigates late toxicity. Adverse events are recorded in a centralized database, enabling real‑time pharmacovigilance and continuous protocol improvement. The evidence supports IG‑SRT as a low‑risk, cosmetically favorable modality for early‑stage NMSC, with toxicity rates comparable to or lower than surgery or conventional radiotherapy.
Each patient’s treatment plan is reviewed by a multidisciplinary team to tailor dose and fractionation, ensuring optimal balance between efficacy and cosmetic preservation. Yes.
Future Trends and Emerging Research
Adaptive IG‑SRT, AI‑driven planning, and real‑time imaging enhance precision. Trials target melanoma and basal cell variants, exploring dose‑sparing protocols and wearable sensors for motion tracking. Future trials refine dose‑opt and capture outcomes .
Adaptive IG‑SRT merges daily imaging with automated plan updates, adjusting dose in response to skin contour changes, edema, or motion. Real‑time guidance uses high‑resolution surface scanners and optical tracking to confirm applicator placement before each fraction. This closed‑loop system captures the lesion geometry, recalculates the dose, and delivers the updated plan within seconds. The dynamic workflow reduces marginal misses by up to 30 % and improves cosmetic outcomes, especially for mobile sites like the face and neck. Emerging research employs machine‑learning models to predict daily skin deformation, enabling pre‑emptive plan adaptation. Wearable sensors provide continuous motion data, triggering automatic couch adjustments. Clinical trials are validating adaptive IG‑SRT in recurrent and re‑treatment settings, aiming to preserve local control while limiting late toxicity. Future directions include hybrid imaging—combining optical coherence tomography with surface imaging—to visualize sub‑surface lesions during treatment. The integration of adaptive planning, real‑time guidance, and AI‑driven prediction is poised to elevate IG‑SRT to precision therapy with reduced morbidity. Studies also explore the use of photon‑counting detectors for dose verification, and the potential for integrating radiobiological models to tailor fractionation schedules. Regulatory pathways are adapting to accommodate adaptive workflows, with new guidelines on quality assurance and data management emerging to support widespread clinical adoption. Patient comfort is enhanced by shorter treatment times, fewer clinic visits, and improved quality of life.
Artificial Intelligence in Treatment Planning
Artificial intelligence (AI) is transforming IG‑SRT planning by automating contour delineation, dose optimization, and quality assurance. Convolutional neural networks trained on thousands of dermoscopic images can identify basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) lesions with >95 % accuracy, reducing inter‑observer variability. AI‑driven dose‑volume histograms predict skin toxicity, enabling clinicians to adjust fractionation schemes in real time. Machine‑learning algorithms analyze patient‑specific factors—age, skin phototype, lesion depth—to generate personalized treatment plans that balance efficacy and cosmetic outcome. Integration with the IG‑SRT console allows the system to ingest daily surface scans, compare them to the baseline plan, and recommend plan modifications within minutes, thereby supporting adaptive therapy. Validation studies report that AI‑assisted plans achieve comparable local control rates to expert‑crafted plans while shortening planning time by 40 %. Ongoing trials are evaluating reinforcement‑learning models that continuously refine dose distributions based on early response metrics, potentially improving cure rates for recurrent lesions. Regulatory frameworks are evolving to certify AI tools as medical devices, emphasizing transparency, explainability, and rigorous clinical validation. As AI matures, its role in IG‑SRT will expand from planning support to real‑time treatment adaptation, promising higher precision, reduced toxicity, and streamlined workflows for dermatologic oncologists worldwide!!!
Image‑guided superficial radiation therapy (IG‑SRT) has proven highly effective for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Recent clinical data suggest that its precise, low‑energy delivery can target other cutaneous neoplasms with minimal morbidity. Melanoma in situ, lentigo maligna, and cutaneous metastases from visceral primaries are emerging candidates for IG‑SRT, especially when surgical excision is contraindicated or would compromise cosmesis. Early phase trials report local control rates exceeding 90 % for thin melanoma lesions treated with 20 Gy in 10 fractions, while adaptive IG‑SRT protocols have shown promising results for lentigo maligna, achieving 95 % clearance with acceptable pigmentary changes. Additionally, IG‑SRT is being evaluated for Merkel cell carcinoma and dermatofibrosarcoma protuberans, where its shallow dose fall‑off preserves surrounding tissue and reduces radiation‑induced fibrosis. These developments promise to position IG‑SRT as a cornerstone of multidisciplinary skin cancer care, offering tailored, patient‑centric treatment options worldwide. Current trials are exploring dose escalation strategies, aiming to reduce fraction numbers while maintaining local control, which could enhance patient convenience and reduce clinic visits. Moreover, the integration of AI‑driven contouring and adaptive planning is expected to streamline workflows, allowing clinicians to deliver IG‑SRT with greater precision and consistency across diverse clinical settings. In addition, emerging evidence indicates that IG‑SRT may be safely combined with topical immunomodulators to enhance anti‑tumor immune responses, potentially improving outcomes for lesions in immunocompromised patients or those with extensive field cancerization. Ongoing multicenter registries will further clarify long‑term cosmetic outcomes and secondary malignancy risks, ensuring that IG‑SRT remains a safe modality for cutaneous malignancies.
